A digital SERS platform powered by bispecific antibody fragments for SARS-CoV-2 diagnostics
Biosensors and Bioelectronics · 2026
DOI: 10.1016/j.bios.2025.118252 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biosensors and Bioelectronics, 2026. Verfasst von Jing Wang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of OptoElectronic Science and Technology for Medicine of Ministry of Education, Fujian Provincial Key Laboratory of Photonics Technolo…. Hauptthemen laut MEDLINE: Spectrum Analysis, Raman, Antibodies, Bispecific, SARS-CoV-2, COVID-19. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Cancer Australia, National Health and Medical Research Council, Queensland Government.
Abstract (Originalsprache)
Surface-enhanced Raman scattering (SERS) immunoassays are powerful analytical tools for protein detection while typically rely on the availability of suitable antibodies. Compared to full-length antibodies, antibody fragments provide advantages such as rapid and cost-effective production. However, oriented conjugation of antibody fragments to SERS nanotags, essential for maintaining their functionality, remains relatively underexplored. Here, we introduce a bispecific antibody (BsAb)-programmable digital immunochemistry detection regime implemented on an advanced digital SERS platform ("DigibiSERS"), enabling deterministic molecular orientation, variance-robust single-particle event calling, and kinetic regularization within one unified platform. Specifically, we fuse an anti-nucleocapsid nanobody with a single-chain variable fragment targeting methoxy polyethylene glycol (mPEG) grafted onto the SERS nanotag surfaces. This design facilitates straightforward, oriented BsAb conjugation, preserving its functionality. The DigibiSERS platform, incorporating single-particle active SERS nanotags, nanomixing-enhanced microchips, and digital readouts, demonstrates high sensitivity and specificity, achieving detection limits of 2.01 ng/mL for nucleocapsid protein and 2.7 copies/mL for virus. An area under the curve (AUC) of 0.8783 highlights the potential of engineered antibody fragments in enhancing the clinical sensitivity and practicality of SERS-based immunoassays for infectious disease diagnostics.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Key Laboratory of OptoElectronic Science and Technology for Medicine of Ministry of Education, Fujian Provincial Key Laboratory of Photonics Technology, Fujian Normal University, Fuzhou, 350117, China; Centre for Person…
- Centre for Personalized Nanomedicine, Australian Institute for Bioengineering and Nanotechnology (AIBN), The University of Queensland, Brisbane, QLD, 4072, Australia.
- Centre for Clinical Research, Faculty of Medicine, The University of Queensland, Royal Brisbane and Women's Hospital, Brisbane, QLD, 4006, Australia; Queensland Paediatric Infectious Diseases (QPID) Sakzewski Laboratory…
- Centre for Personalized Nanomedicine, Australian Institute for Bioengineering and Nanotechnology (AIBN), The University of Queensland, Brisbane, QLD, 4072, Australia. Electronic address: c.howard2@uq.edu.au.
- Centre for Personalized Nanomedicine, Australian Institute for Bioengineering and Nanotechnology (AIBN), The University of Queensland, Brisbane, QLD, 4072, Australia; School of Chemistry and Molecular Biosciences, The U…
Förderung
- Cancer Australia
- National Health and Medical Research Council
- Queensland Government
- Australian Institute for Bioengineering and Nanotechnology, University of Queensland
- Australian National Fabrication Facility
- University of Queensland
- Australian Research Council
Zitieren
APA
Wang, J., Zhou, Q., Lowry, K., Howard, C. B., & Trau, M. (2026). A digital SERS platform powered by bispecific antibody fragments for SARS-CoV-2 diagnostics. Biosensors and Bioelectronics. https://doi.org/10.1016/j.bios.2025.118252
Vancouver
Wang J, Zhou Q, Lowry K, Howard CB, Trau M. A digital SERS platform powered by bispecific antibody fragments for SARS-CoV-2 diagnostics. Biosensors and Bioelectronics. 2026. doi:10.1016/j.bios.2025.118252
BibTeX
@article{Wang2026,
author = {Wang, Jing and Zhou, Quan and Lowry, Kym and Howard, Christopher B and Trau, Matt},
title = {A digital SERS platform powered by bispecific antibody fragments for SARS-CoV-2 diagnostics},
journal = {Biosensors and Bioelectronics},
year = {2026},
doi = {10.1016/j.bios.2025.118252}
}
EUVIMED